Today: November 25, 2017, 12:58 am

"Vitiligo - Pipeline Review, H1 2017" now available at Fast Market Research

New Drug Pipeline market report from Global Markets Direct: "Vitiligo - Pipeline Review, H1 2017"
"Vitiligo - Pipeline Review, H1 2017" now available at Fast Market Research 2017-05-19 17:05:49
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vitiligo - Pipeline Review, H1 2017, provides an overview of the Vitiligo (Dermatology) pipeline landscape.

Vitiligo is a condition in which skin loses melanin, the pigment that determines the color of skin, hair and eyes. Symptoms include premature whitening or graying of the hair on scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of mouth and loss of or change in color of the inner layer of eye. Treatment includes corticosteroid therapy, immunomodulators and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vitiligo - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vitiligo (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Full Report Details at
- ..

The Vitiligo (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.

Vitiligo (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

* The pipeline guide provides a snapshot of the global therapeutic landscape of Vitiligo (Dermatology).
* The pipeline guide reviews pipeline therapeutics for Vitiligo (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
* The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
* The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
* The pipeline guide reviews key companies involved in Vitiligo (Dermatology) therapeutics and enlists all their major and minor projects.
* The pipeline guide evaluates Vitiligo (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
* The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
* The pipeline guide reviews latest news related to pipeline therapeutics for Vitiligo (Dermatology)

Reasons to Get this Report

* Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
* Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
* Find and recognize significant and varied types of therapeutics under development for Vitiligo (Dermatology).
* Classify potential new clients or partners in the target demographic.
* Develop tactical initiatives by understanding the focus areas of leading companies.
* Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
* Formulate corrective measures for pipeline projects by understanding Vitiligo (Dermatology) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in this Report: Aclaris Therapeutics Inc, Biocon Ltd, Bristol-Myers Squibb Company, Celgene Corp, Clinuvel Pharmaceuticals Ltd, Incyte Corp

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

Press Information

Published by
Bill Thompson

# 810 Words
Related Articles
More From The Author
New Report Available: Rheumatoid Arthritis Therapeutics in [..]
Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. [..]
New Market Research Report: Mexico Endoscopy Fluid [..]
GlobalData's new report, "Mexico Endoscopy Fluid Management Systems Market Outlook to 2023", provides key market data [..]
Report Published: "Eosinophilic Esophagitis - Pipeline [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, [..]
New market study, "Global Smart Backpack Market [..]
Smart backpacks are a new generation of luggage that features some advanced technological enhancements such as embedded sensors, [..]
Now Available: Crohn's Disease (Regional Enteritis) - [..]
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease (Regional Enteritis) - [..]
More From Health
Cannabis revolution brings unintended advancements
With the acceleration of technology and it's ever-growing, widespread use, the cannabis industry is not isolate from this societal [..]
World Diabetes Day: Combating diabetic retinopathy in [..]
News release Preventing the preventable: Combating diabetic retinopathy in at risk women November 14, 2017 - report from Los [..]
Singapore eDevelopment's Biomedical Subsidiary Confirms 100% [..]
SINGAPORE, Nov 1, 2017 - (ACN Newswire) - Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today [..]
Endovision’s Range of Portable LED Examination Lights [..]
Endovision Australia, a leader in providing surgical instruments, has a range of portable LED examination lights that are excellent [..]
SGX-Listed Singapore eDevelopment Subsidiary Global BioLife [..]
SINGAPORE, Oct 24, 2017 - (ACN Newswire) - SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that U.S. [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.